BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
EPA:BLC - Euronext Paris - Matif - FR0000035370 - Common Stock - Currency: EUR
BLC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 26 industry peers in the Health Care Providers & Services industry. BLC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BLC has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BLC was profitable.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
Each year in the past 5 years BLC had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of 0.25%, BLC is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
The Return On Equity of BLC (2.25%) is worse than 61.54% of its industry peers.
With a decent Return On Invested Capital value of 5.65%, BLC is doing good in the industry, outperforming 65.38% of the companies in the same industry.
BLC had an Average Return On Invested Capital over the past 3 years of 5.34%. This is in line with the industry average of 5.89%.
The last Return On Invested Capital (5.65%) for BLC is above the 3 year average (5.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROIC | 5.65% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
1.3 Margins
BLC has a Profit Margin of 0.32%. This is in the lower half of the industry: BLC underperforms 65.38% of its industry peers.
BLC has a Operating Margin of 7.67%. This is in the better half of the industry: BLC outperforms 61.54% of its industry peers.
BLC's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 67.54%, BLC is in the better half of the industry, outperforming 73.08% of the companies in the same industry.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.67% | ||
| PM (TTM) | 0.32% | ||
| GM | 67.54% |
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
BLC has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLC has more shares outstanding
Compared to 1 year ago, BLC has an improved debt to assets ratio.
2.2 Solvency
BLC has an Altman-Z score of 1.41. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.41, BLC perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
BLC has a debt to FCF ratio of 9.33. This is a negative value and a sign of low solvency as BLC would need 9.33 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.33, BLC is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Debt/Equity ratio of 5.20 is on the high side and indicates that BLC has dependencies on debt financing.
The Debt to Equity ratio of BLC (5.20) is worse than 80.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Altman-Z | 1.41 |
ROIC/WACC1.17
WACC4.84%
2.3 Liquidity
BLC has a Current Ratio of 1.19. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.19, BLC is in the better half of the industry, outperforming 61.54% of the companies in the same industry.
BLC has a Quick Ratio of 1.19. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
BLC has a Quick ratio of 0.96. This is comparable to the rest of the industry: BLC outperforms 57.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The earnings per share for BLC have decreased strongly by -71.43% in the last year.
Looking at the last year, BLC shows a small growth in Revenue. The Revenue has grown by 3.24% in the last year.
The Revenue has been growing by 9.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
Revenue 1Y (TTM)3.24%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%3.96%
3.2 Future
BLC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.74% yearly.
Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 5.06% on average per year.
EPS Next Y9.69%
EPS Next 2Y14.54%
EPS Next 3Y15.74%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y6.99%
Revenue Next 3Y6.96%
Revenue Next 5Y5.06%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 131.59, BLC can be considered very expensive at the moment.
69.23% of the companies in the same industry are cheaper than BLC, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.32, BLC is valued quite expensively.
Based on the Price/Forward Earnings ratio of 8.47, the valuation of BLC can be described as reasonable.
BLC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 92.31% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.19. BLC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 131.59 | ||
| Fwd PE | 8.47 |
4.2 Price Multiples
80.77% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
BLC's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BLC is cheaper than 76.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.73 | ||
| EV/EBITDA | 5.95 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLC does not grow enough to justify the current Price/Earnings ratio.
BLC's earnings are expected to grow with 15.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)13.58
PEG (5Y)N/A
EPS Next 2Y14.54%
EPS Next 3Y15.74%
5. Dividend
5.1 Amount
BLC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (6/18/2025, 3:41:39 PM)
28.95
+0.25 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners9.28%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap213.07M
Analysts83.33
Price Target33.66 (16.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-3.5%
DP42.86%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.79%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)25.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 131.59 | ||
| Fwd PE | 8.47 | ||
| P/S | 0.39 | ||
| P/FCF | 4.73 | ||
| P/OCF | 1.9 | ||
| P/B | 2.8 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.95 |
EPS(TTM)0.22
EY0.76%
EPS(NY)3.42
Fwd EY11.81%
FCF(TTM)6.13
FCFY21.16%
OCF(TTM)15.24
OCFY52.63%
SpS73.4
BVpS10.34
TBVpS-19.17
PEG (NY)13.58
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROCE | 8.61% | ||
| ROIC | 5.65% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 10.3% | ||
| OM | 7.67% | ||
| PM (TTM) | 0.32% | ||
| GM | 67.54% | ||
| FCFM | 8.35% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
ROICexc(3y)5.7%
ROICexc(5y)5.58%
ROICexgc(3y)12.68%
ROICexgc(5y)11.8%
ROCE(3y)8.16%
ROCE(5y)7.93%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y1.85%
ROICexc growth 3Y8.09%
ROICexc growth 5Y5.81%
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Debt/EBITDA | 3.72 | ||
| Cap/Depr | 103.59% | ||
| Cap/Sales | 12.41% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.61% | ||
| Profit Quality | 2640.05% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 1.41 |
F-Score6
WACC4.84%
ROIC/WACC1.17
Cap/Depr(3y)89.47%
Cap/Depr(5y)88.81%
Cap/Sales(3y)10.8%
Cap/Sales(5y)10.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
EPS Next Y9.69%
EPS Next 2Y14.54%
EPS Next 3Y15.74%
EPS Next 5YN/A
Revenue 1Y (TTM)3.24%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%3.96%
Revenue Next Year7.14%
Revenue Next 2Y6.99%
Revenue Next 3Y6.96%
Revenue Next 5Y5.06%
EBIT growth 1Y3.82%
EBIT growth 3Y9.86%
EBIT growth 5Y16.32%
EBIT Next Year166.67%
EBIT Next 3Y44.23%
EBIT Next 5YN/A
FCF growth 1Y197.72%
FCF growth 3Y10.22%
FCF growth 5Y6.95%
OCF growth 1Y63.86%
OCF growth 3Y7.62%
OCF growth 5Y8.72%